Open-label Extension Study of Brazikumab in Crohn's Disease

Inclusion Criteria:

1. Male or female participants with successful completion or early termination due tolack of efficacy from Study D5271C00001 (Legacy #3150-301-008). Meets 1 of the following criteria for successful completion or early termination dueto lack of efficacy from Study D5271C00001 (Legacy #3150-301-008):
2. A participant is considered to have completed the D5271C00001 (Legacy

#3150-301-008) study if they have received scheduled study interventions,completed scheduled visits, and completed Week 52 assessments. 2. A participant in Study D5271C00001 (Legacy #3150-301-008) who discontinued fromthe study due to lack of efficacy after a minimum of 12 weeks of double-blindtreatment and met criteria for the use of rescue treatment in the lead-inprotocol. 2. Criterion deleted as part of Amendment. 3. Each participant must have had the ileocolonoscopic procedure at the final visit (Week 52, Week 12, or early termination after Week 12 of Study D5271C00001 (Legacy # 3150-301-008). 4. Female participants of childbearing potential must have a negative urine pregnancytest prior to administration of study intervention and must agree to use a highlyeffective method of birth control (confirmed by the investigator) from signing the ICFthroughout the study duration and for at least 18 weeks after last dose of studyintervention. 5. Women not of childbearing potential are defined as women who are either permanentlysterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or whoare postmenopausal. Women will be considered postmenopausal if they have beenamenorrhoeic for 12 months prior to signing the ICF without an alternative medicalcause. 6. Nonsterilized males who are sexually active with a female partner of childbearingpotential must comply with the methods of contraception during treatment and until theend of relevant systemic exposure in the male participant, plus a further 18 weeks. 7. Capable of giving signed informed consent which includes compliance with therequirements and restrictions listed in the ICF and in this protocol. 8. Written informed consent from the participant has been obtained prior to any studyrelated procedures. 9. Legally authorized representative consent has been obtained (if applicable). 10. Written documentation has been obtained in accordance with the relevant country andlocal privacy requirements, where applicable. 11. Demonstration of adequate compliance with the study procedures in Study D5271C00001 (Legacy #3150 301-008) in the opinion of the investigator and/or sponsor. 12. Willingness and ability to attend all study visits, comply with the study procedures,read and write in order to complete questionnaires, and be able to complete the study. Complete inclusion criteria are in the study protocol

Exclusion Criteria:

1. Any participant with an unresolved AE from the Study D5271C00001 (Legacy #3150 301-008) that would limit the participant's ability to participate in or complete thisstudy.
2. Current diagnosis of ischemic colitis, colonic mucosal dysplasia, or primarysclerosing cholangitis.
3. Organ or cell-based transplantation (eg, islet cell transplantation or autologous stemcell transplantation) with the exception of corneal transplant.
4. Any other condition or finding that, in the investigator's or sponsor's opinion, wouldeither confound proper interpretation of the study or expose a participant tounacceptable risk.
5. History of cancer except for basal cell and/or squamous cell carcinoma of the skin,and carcinoma in situ of the cervix within 12 months of screening.
6. Participant meets criteria for discontinuation of study intervention during prior theD5271C00001 (Legacy #3150 301-008) study (excluding lack of efficacy).
7. Criterion deleted as part of Amendment.
8. Known history of primary immunodeficiency, splenectomy, or any underlying conditionthat predisposes the subject to infection, including HIV infection.
9. Prolonged QTcF interval (QTc >450 msec or QTC >480 for participants with bundle branchblock; determined by central ECG), or conditions leading to additional risk for QTprolongation (eg, congenital long-QT syndrome).
10. Clinically significant kidney disease including but not limited to: (a) Chronic kidney disease with an estimated glomerular filtration rate of less than 30 ml/min calculated by MDRD equation, as applicable, by the central laboratory atscreening are excluded.
11. Participant requires additional immunosuppressive therapy (aside from permittedconcomitant medication), biological treatment, or prohibited treatment.
12. Participant received a Bacille Calmette-Guérin vaccination within 12 months of Week 0 (Visit 1) or any other live vaccine < 4 weeks prior to Week 0 (Visit 1) or is planningto receive any such vaccine over the course of the study.
13. Participant received a prohibited medication during participation in the lead-in studyor during screening for this study.
14. Participant is planning to receive an investigational drug (other than studyintervention) or investigational device at any time during Study D5271C00002 (Legacy

#3150-303-008) with the exception of "registry" or "cohort" trials. 15. Participants with a known hypersensitivity to brazikumab or any of the excipients ofthe product. 16. Protocol-defined abnormal laboratory results at screening. 17. Females who arepregnant, nursing, or planning a pregnancy during the study OR females who are ofchildbearing potential and do not agree to use a highly effective method ofcontraception consistently and correctly.

18 Participant is directly or indirectly involved in the conduct and administration of thisstudy as an investigator, subinvestigator, study coordinator, other study staff member, oremployee of AstraZeneca, or the participant is a first-degree family member, significantother, or relative residing with one of the above persons involved directly or indirectlyin the study; or the participant is enrolled in this study at another clinical study site.

19 Involvement in the planning and/or conduct of the study (applies to both AstraZenecastaff and/or staff at the study site).

20 Judgment by the investigator that the participant should not participate in the study ifthe participant is unlikely to comply with study procedures, restrictions, andrequirements.

21 Previous participation in the present study. Complete exclusion criteria are in the study protocol